SCHEMBL3480798

SCHEMBL3480798

CCOC(CSc1ccc(OC)cc1Cl)OCC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.36
HTR3A P46098 1/20 0.36
PPARD Q03181 2/20 0.34
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
SLC6A4 P31645 5/20 0.33
HTR2A P28223 4/20 0.33
KCNH2 Q12809 3/20 0.33
ALDH1A1 P00352 2/20 0.33
FFAR1 O14842 1/20 0.33
GFER P55789 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2E1 P05181 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C8 P10632 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2B6 P20813 1/20 0.32
CYP2C19 P33261 1/20 0.32
SLC6A2 P23975 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3643403 0.84 CYP3A4 (0.36) ALDH1A1CYP1A2CYP2E1CYP3A4CYP2C8
SCHEMBL19436121 0.81 TSHR (0.36) ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL19731308 0.77 TRPV4 (0.36) SLC6A4HTR2AALDH1A1SLC6A2SLC6A3
SCHEMBL594533 0.76 BACE1 (0.42) ALDH1A1KDM4E
SCHEMBL30489921 0.76 BACE1 (0.42) ALDH1A1KDM4E
SCHEMBL27989900 0.76 CYP1A2 (0.37) PTGS1HTR2AALDH1A1CYP1A2CYP2E1
SCHEMBL17400964 0.74 APP (0.44) ALDH1A1CYP1A2KDM4E
SCHEMBL13031828 0.74 GAA (0.33) ALDH1A1
SCHEMBL4423068 0.74 TDP1 (0.40) SLC6A4ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL228468 0.73 MTNR1A (0.53) HRH1CCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049200-B1 NOVEL INHIBITORS OF BETA-LACTAMASE METHYLGENE INC (CA) 2015-04-29 EP disclosed
US-8440643-B2 Inhibitors of beta-lactamase METHYLGENE INC. (CA) 2013-05-14 US disclosed
US-20100317625-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE 92229129 QUEBEC INC. (CA) 2010-12-16 US disclosed
US-20100279983-A1 NOVEL INHIBITORS OF BETA-LACTAMASE METHYLGENE INC. 2010-11-04 US disclosed
EP-2049200-A2 NOVEL INHIBITORS OF BETA-LACTAMASE MethylGene Inc. (CA) 2009-04-22 EP disclosed
EP-2024376-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE Merck & Co., Inc. (US) 2009-02-18 EP disclosed
WO-2008073142-A2 NOVEL INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2008-06-19 WO disclosed
WO-2007139729-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317625-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE MGAM, BPGM, PPME1 HTR1A 4584/4885HTR3A 4504/4885PPARD 1080/4885
US-20100279983-A1 NOVEL INHIBITORS OF BETA-LACTAMASE MGAM, MGAM2, PGLS HTR1A 4451/4885HTR3A 4364/4885PPARD 2663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.